Childhood Epilepsy with Occipital Paroxysm: Classification, Atypical Evolution and Long-Term Prognosis in 35 Patients

Ayşe Aksoy1, Göknur Haliloğlu, Dilek Yalnızoğlu

  • 1Department of Pediatrics, Hacettepe University Faculty of Medicine; Dr. Sami Ulus Children's Hospital, Ankara, Turkey. aysechild@gmail.com.

Insights

Childhood epilepsy with occipital paroxysms (CEOP) can present with atypical symptoms like vomiting and visual disturbances. Management should consider mixed clinical findings rather than strict age-based classifications.

Area of Science:

  • Neurology
  • Pediatric Neurology

Background:

  • Childhood epilepsy with occipital paroxysms (CEOP) encompasses various syndromes with distinct clinical and EEG features.
  • Understanding atypical presentations is crucial for accurate diagnosis and management of CEOP.

Purpose of the Study:

  • To analyze the clinical and EEG characteristics of CEOP, focusing on atypical ictal symptoms, evolution, and outcomes.
  • To evaluate the current classification of CEOP and its implications for patient management.

Main Methods:

  • Retrospective study of 35 patients diagnosed with CEOP.
  • Classification of patients into Panayiotopoulos syndrome, Gastaut syndrome, and mixed types.
  • Detailed analysis of ictal symptoms, EEG findings, and patient evolution.

Main Results:

  • Nine patients (25%) with mixed-type CEOP exhibited atypical ictal manifestations including vomiting, visual symptoms, eye deviation, and headaches.
  • Five patients demonstrated atypical evolutionary patterns.
  • The study suggests that strict delineation into early-onset or late-onset CEOP may be inappropriate due to mixed clinical findings across ages.

Conclusions:

  • CEOP can present with significant atypical symptoms and evolutionary patterns, particularly in mixed types.
  • A flexible approach to CEOP classification, considering mixed clinical findings irrespective of age, is recommended.
  • Further investigation into the reasons behind atypical CEOP presentations and age-related evolution is warranted.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
902
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K